The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: Insights from the AVERROES trial

Stefan H. Hohnloser, Olga Shestakovska, John Eikelboom, Maria Grazia Franzosi, Ru San Tan, Jun Zhu, Salim Yusuf, Stuart J. Connolly

Research output: Contribution to journalArticle

Abstract

AimsThe aim of this study was to evaluate the effects of apixaban, a novel oral factor Xa inhibitor, on the need for cardiovascular hospitalization.Methods and resultsOur analysis is based on data from AVERROES, a randomized double-blind trial testing the efficacy and safety of apixaban against aspirin for the prevention of thrombo-embolism in 5599 atrial fibrillation (AF) patients unsuitable for vitamin K antagonist therapy. Hospitalizations were captured by dedicated case report forms and the outcome variable was time from randomization to the first hospitalization. Effects of treatment with apixaban on the rates of cardiovascular and non-cardiovascular hospitalizations were assessed using Cox proportional hazards regression models. During a mean follow-up of 1.1 years, 800 patients were hospitalized at least once for cardiovascular reasons, 442 (15.4%/year) in the aspirin group, 358 (12.3%) in the apixaban group [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.69-0.92; P = 0.002]. The reduction in cardiovascular hospitalization in the apixaban arm was predominantly due to a reduction in hospitalization for strokes, but there were also fewer hospitalizations for other cardiovascular causes. Patients with paroxysmal AF were significantly more likely to be hospitalized for AF treatment, whereas more heart failure admissions occurred in patients with permanent AF. Assignment to apixaban was the only independent predictor for a reduction in hospitalization. Cardiovascular hospitalization was the strongest independent predictor of subsequent mortality (HR: 3.95, 95% CI: 3.06-5.09; P <0.001).ConclusionIn AVERROES, patients on apixaban therapy were less likely to be hospitalized. This may have important consequences for patients' well-being and for healthcare resources.This trial is registered underClinicalTrials.gov number, NCT00496769.

Original languageEnglish
Pages (from-to)2752-2759
Number of pages8
JournalEuropean Heart Journal
Volume34
Issue number35
DOIs
Publication statusPublished - Sep 14 2013

Fingerprint

Atrial Fibrillation
Hospitalization
Aspirin
Confidence Intervals
apixaban
Vitamin K
Therapeutics
Random Allocation
Embolism
Proportional Hazards Models
Heart Failure
Stroke
Delivery of Health Care
Safety
Mortality

Keywords

  • Anticoagulation
  • Apixaban
  • Atrial fibrillation
  • Hospitalization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hohnloser, S. H., Shestakovska, O., Eikelboom, J., Franzosi, M. G., Tan, R. S., Zhu, J., ... Connolly, S. J. (2013). The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: Insights from the AVERROES trial. European Heart Journal, 34(35), 2752-2759. https://doi.org/10.1093/eurheartj/eht292

The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation : Insights from the AVERROES trial. / Hohnloser, Stefan H.; Shestakovska, Olga; Eikelboom, John; Franzosi, Maria Grazia; Tan, Ru San; Zhu, Jun; Yusuf, Salim; Connolly, Stuart J.

In: European Heart Journal, Vol. 34, No. 35, 14.09.2013, p. 2752-2759.

Research output: Contribution to journalArticle

Hohnloser, SH, Shestakovska, O, Eikelboom, J, Franzosi, MG, Tan, RS, Zhu, J, Yusuf, S & Connolly, SJ 2013, 'The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: Insights from the AVERROES trial', European Heart Journal, vol. 34, no. 35, pp. 2752-2759. https://doi.org/10.1093/eurheartj/eht292
Hohnloser, Stefan H. ; Shestakovska, Olga ; Eikelboom, John ; Franzosi, Maria Grazia ; Tan, Ru San ; Zhu, Jun ; Yusuf, Salim ; Connolly, Stuart J. / The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation : Insights from the AVERROES trial. In: European Heart Journal. 2013 ; Vol. 34, No. 35. pp. 2752-2759.
@article{f6297f77e8864d278461db2b8473da7c,
title = "The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: Insights from the AVERROES trial",
abstract = "AimsThe aim of this study was to evaluate the effects of apixaban, a novel oral factor Xa inhibitor, on the need for cardiovascular hospitalization.Methods and resultsOur analysis is based on data from AVERROES, a randomized double-blind trial testing the efficacy and safety of apixaban against aspirin for the prevention of thrombo-embolism in 5599 atrial fibrillation (AF) patients unsuitable for vitamin K antagonist therapy. Hospitalizations were captured by dedicated case report forms and the outcome variable was time from randomization to the first hospitalization. Effects of treatment with apixaban on the rates of cardiovascular and non-cardiovascular hospitalizations were assessed using Cox proportional hazards regression models. During a mean follow-up of 1.1 years, 800 patients were hospitalized at least once for cardiovascular reasons, 442 (15.4{\%}/year) in the aspirin group, 358 (12.3{\%}) in the apixaban group [hazard ratio (HR) 0.80, 95{\%} confidence interval (CI) 0.69-0.92; P = 0.002]. The reduction in cardiovascular hospitalization in the apixaban arm was predominantly due to a reduction in hospitalization for strokes, but there were also fewer hospitalizations for other cardiovascular causes. Patients with paroxysmal AF were significantly more likely to be hospitalized for AF treatment, whereas more heart failure admissions occurred in patients with permanent AF. Assignment to apixaban was the only independent predictor for a reduction in hospitalization. Cardiovascular hospitalization was the strongest independent predictor of subsequent mortality (HR: 3.95, 95{\%} CI: 3.06-5.09; P <0.001).ConclusionIn AVERROES, patients on apixaban therapy were less likely to be hospitalized. This may have important consequences for patients' well-being and for healthcare resources.This trial is registered underClinicalTrials.gov number, NCT00496769.",
keywords = "Anticoagulation, Apixaban, Atrial fibrillation, Hospitalization",
author = "Hohnloser, {Stefan H.} and Olga Shestakovska and John Eikelboom and Franzosi, {Maria Grazia} and Tan, {Ru San} and Jun Zhu and Salim Yusuf and Connolly, {Stuart J.}",
year = "2013",
month = "9",
day = "14",
doi = "10.1093/eurheartj/eht292",
language = "English",
volume = "34",
pages = "2752--2759",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "35",

}

TY - JOUR

T1 - The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation

T2 - Insights from the AVERROES trial

AU - Hohnloser, Stefan H.

AU - Shestakovska, Olga

AU - Eikelboom, John

AU - Franzosi, Maria Grazia

AU - Tan, Ru San

AU - Zhu, Jun

AU - Yusuf, Salim

AU - Connolly, Stuart J.

PY - 2013/9/14

Y1 - 2013/9/14

N2 - AimsThe aim of this study was to evaluate the effects of apixaban, a novel oral factor Xa inhibitor, on the need for cardiovascular hospitalization.Methods and resultsOur analysis is based on data from AVERROES, a randomized double-blind trial testing the efficacy and safety of apixaban against aspirin for the prevention of thrombo-embolism in 5599 atrial fibrillation (AF) patients unsuitable for vitamin K antagonist therapy. Hospitalizations were captured by dedicated case report forms and the outcome variable was time from randomization to the first hospitalization. Effects of treatment with apixaban on the rates of cardiovascular and non-cardiovascular hospitalizations were assessed using Cox proportional hazards regression models. During a mean follow-up of 1.1 years, 800 patients were hospitalized at least once for cardiovascular reasons, 442 (15.4%/year) in the aspirin group, 358 (12.3%) in the apixaban group [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.69-0.92; P = 0.002]. The reduction in cardiovascular hospitalization in the apixaban arm was predominantly due to a reduction in hospitalization for strokes, but there were also fewer hospitalizations for other cardiovascular causes. Patients with paroxysmal AF were significantly more likely to be hospitalized for AF treatment, whereas more heart failure admissions occurred in patients with permanent AF. Assignment to apixaban was the only independent predictor for a reduction in hospitalization. Cardiovascular hospitalization was the strongest independent predictor of subsequent mortality (HR: 3.95, 95% CI: 3.06-5.09; P <0.001).ConclusionIn AVERROES, patients on apixaban therapy were less likely to be hospitalized. This may have important consequences for patients' well-being and for healthcare resources.This trial is registered underClinicalTrials.gov number, NCT00496769.

AB - AimsThe aim of this study was to evaluate the effects of apixaban, a novel oral factor Xa inhibitor, on the need for cardiovascular hospitalization.Methods and resultsOur analysis is based on data from AVERROES, a randomized double-blind trial testing the efficacy and safety of apixaban against aspirin for the prevention of thrombo-embolism in 5599 atrial fibrillation (AF) patients unsuitable for vitamin K antagonist therapy. Hospitalizations were captured by dedicated case report forms and the outcome variable was time from randomization to the first hospitalization. Effects of treatment with apixaban on the rates of cardiovascular and non-cardiovascular hospitalizations were assessed using Cox proportional hazards regression models. During a mean follow-up of 1.1 years, 800 patients were hospitalized at least once for cardiovascular reasons, 442 (15.4%/year) in the aspirin group, 358 (12.3%) in the apixaban group [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.69-0.92; P = 0.002]. The reduction in cardiovascular hospitalization in the apixaban arm was predominantly due to a reduction in hospitalization for strokes, but there were also fewer hospitalizations for other cardiovascular causes. Patients with paroxysmal AF were significantly more likely to be hospitalized for AF treatment, whereas more heart failure admissions occurred in patients with permanent AF. Assignment to apixaban was the only independent predictor for a reduction in hospitalization. Cardiovascular hospitalization was the strongest independent predictor of subsequent mortality (HR: 3.95, 95% CI: 3.06-5.09; P <0.001).ConclusionIn AVERROES, patients on apixaban therapy were less likely to be hospitalized. This may have important consequences for patients' well-being and for healthcare resources.This trial is registered underClinicalTrials.gov number, NCT00496769.

KW - Anticoagulation

KW - Apixaban

KW - Atrial fibrillation

KW - Hospitalization

UR - http://www.scopus.com/inward/record.url?scp=84890062417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890062417&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/eht292

DO - 10.1093/eurheartj/eht292

M3 - Article

C2 - 23892201

AN - SCOPUS:84890062417

VL - 34

SP - 2752

EP - 2759

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 35

ER -